BridgeBio Pharma gains after H.C. Wainwright raises PT

Shares of drugmaker BridgeBio Pharma BBIO.O rise 2.7% to $39.67

Brokerage H.C. Wainwright raises PT to $56 from $53

Believe BBIO's rare heart disease drug, acoramidis, could reach annualized revenue run rate of more than $1 billion in mid- to late 2027 in the U.S. — H.C. Wainwright

Acoramidis reduced incidence of atrial fibrillation events in patients with transthyretin amyloid cardiomyopathy (ATTR-CM), BBIO said in May

Believe that this evidence, coupled with the growing proof that increased TTR stabilization extent is closely linked to favorable outcomes, should accelerate acoramidis market adoption — brokerage

BBIO has fallen 8.3% YTD, as of last close